US FDA grants Orphan Drug Designation for CRO-67
Filed with ASX · · 2 pages · English
Story so far
Earlier from Noxopharm
- Trading Halt
- Pause in Trading
- Latest CRO-67 data shows success in reducing cancer growth
- Appendix 4E and Audited Financial Statements
- June 2023 Activities Report and Appendix 4C
Later from Noxopharm
- Response to ASX Query
- September 2023 Activities Report and Appendix 4C
- mRNA Vaccine Enhancer Shows Inflammation Reduction
- Noxopharm 2023 AGM Corporate Presentation
- Noxopharm Enhances Cash Position via R&D Rebate
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm